
WHAT IS CLAIMED IS:

1. A compound according to Formula (I)



(I),

or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof, wherein:

m, and n are independently an integer selected from the group consisting of 0, 1, 2, and 3;

p, and q are independently an integer selected from the group consisting of 0, 1, 2, 3, and 4;

R_2, R_{2a}, R_{2b}, R_{2c} and R_{2d} are independently selected from the group consisting of hydrogen, deuterium, amino, hydroxyl, -OD, halogen, cyano, nitro, unsubstituted or substituted C_{1-6} alkyl, unsubstituted or substituted C_{1-6} haloalkyl, unsubstituted or substituted C_{1-6} hydroxyalkyl, unsubstituted or substituted C_{2-6} alkenyl, unsubstituted or substituted C_{2-6} alkenyloxy, unsubstituted or substituted C_{2-6} alkynyl, unsubstituted or substituted C_{2-6} alkynyloxy, unsubstituted or substituted C_{1-8} alkoxy, unsubstituted or substituted C_{3-6} cycloalkyl, unsubstituted or substituted C_{3-6} heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein R_2 is not hydrogen, hydroxy or benzyloxy; or R_2 and R_{2b} or R_{2c}, taken together with the atoms to which they are attached form a ring system; or R_{2a} and R_{2b}, or R_{2c} and R_{2d}, taken together with the atoms to which they are attached form a ring system;


R_3 is selected from hydrogen, deuterium, hydroxyl, -OD, unsubstituted or substituted C_{1-6} alkyl, unsubstituted or substituted C_{1-6} haloalkyl, unsubstituted or substituted C_{1-6} hydroxyalkyl, unsubstituted or substituted C_{2-6} alkenyl, unsubstituted or substituted C_{3-6} cycloalkyl, unsubstituted or substituted C_{3-6} heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R_{4a}, R_{4b}, R_{5a}, and R_{5b}, are independently selected from the group consisting of hydrogen, deuterium, and unsubstituted or substituted C_{1-6} alkyl; wherein when m and n are 1 then R_{4a}, R_{4b}, R_{5a}, R_{5b} are hydrogen;


R_6 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, oxo, -OD, cyano, substituted or unsubstituted C_{1-4} alkyl, and substituted or unsubstituted C_{1-4} alkoxy, substituted or unsubstituted aryl; or R_6 and R_3, taken together with the atoms to which they are attached form a ring system;
R_7 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, oxo, -OD, cyano, substituted or unsubstituted C_{1-4} alkyl, and substituted or unsubstituted C_{1-4} alkoxy;
R_8 is absent, or selected from the group consisting of hydrogen, deuterium, cyano, hydroxyl, -OD, substituted or unsubstituted C_{1-4} alkyl, substituted or unsubstituted C_{2-4} alkenyl, substituted or unsubstituted C_{3-6} cycloalkyl, and substituted or unsubstituted C_{1-4} alkoxy;
X is O or S; and
wherein R_1 and R_{1d} are fluoro, and R_{1a}, R_{1b} and R_{1c} are hydrogen.

2. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to claim 1, wherein R_2 is selected from the group consisting of hydrogen, deuterium, amino, hydroxyl, -OD, halogen, cyano, unsubstituted or substituted C_{1-6} alkyl, unsubstituted or substituted C_{1-6} haloalkyl, unsubstituted or substituted C_{1-6} hydroxyalkyl, unsubstituted or substituted C_{2-6} alkenyl, unsubstituted or substituted C_{1-6} alkoxy, unsubstituted or substituted C_{3-6} cycloalkyl, unsubstituted or substituted C_{3-6} heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R_{2d} is selected from the group consisting of hydrogen, deuterium, amino, hydroxyl, -OD, halogen, cyano, unsubstituted or substituted C_{1-6} alkyl, unsubstituted or substituted C_{1-6} haloalkyl, unsubstituted or substituted C_{1-6} hydroxyalkyl, unsubstituted or substituted C_{2-6} alkenyl, unsubstituted or substituted C_{1-6} alkoxy, unsubstituted or substituted C_{3-6} cycloalkyl, unsubstituted or substituted C_{3-6} heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R_{2a}, R_{2b}, and R_{2c} are hydrogen, and R_{2d} is not hydrogen; or R_{2a}, R_{2c} and R_{2d} are hydrogen and R_2 and R_{2b}, taken together with the atoms to which they are attached form a heteroalicyclic or heteroaryl ring system.


3. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to claim 1 or 2, wherein R_2, R_{2a}, R_{2b}, R_{2c} and R_{2d} independently are selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{2-6} alkenyloxy, C_{1-6} alkynyloxy C_{1-6} haloalkoxy, C_{3-4} cycloalkyl, C_{3-4} cycloalkyl-C_{1-3} alkyl and deuterated analogues thereof; or R_2 and R_{2b}, taken together with the phenyl ring they attach to and the atoms to which they are attached form a bicyclic fused ring system that has the following formulae:




(III) ,




(IV),



(V),



(VI) or



(VII),

wherein R_{12a}, R_{12b}, R_{12c}, R_{13a}, R_{13b}, R_{14a}, and R_{14b} independently are absent or selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C_{1-4} alkyl, and C_{1-4} alkoxy, and wherein Z_1, Z_2 and Z_3 independently are selected from the group consisting of C, N, O and S.

4. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-3, wherein the formed ring system is of Formula (III), and both R_{12a} and R_{12b} are hydrogen or methyl, and both R_{13a} and R_{13b} are hydrogen or methyl.

5. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-4, wherein R_{2a}, R_{2c}, R_{2d}, and R_{2b}, provided R_{2b} is not forming a ring system with R_2, independently are selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, methyl, $-CD_3$, methoxy, $-OCD_3$,$-OCF_3$ and $-CF_3$.

6. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-5, wherein R_{2a}, R_{2c} and R_{2b} are hydrogen, and R_{2d} is hydrogen, fluoro or hydroxyl.


7. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-3, wherein one of R_{2a} and R_{2b} is fluoro and the other is hydrogen, and R_{2c} and R_{2d} are hydrogen.

8. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-7, wherein R_2, provided R_2 is not forming a ring system with R_{2b}, is selected from the group consisting of halogen, cyano, methyl, $-CD_3$, ethyl, $-CD_2CD_3$, optionally deuterated n-propyl, optionally deuterated iso-propyl, optionally deuterated n-butyl, optionally deuterated iso-butyl, optionally deuterated n-pentyl, optionally deuterated 2-methyl-butyl, optionally deuterated n-hexyl, optionally deuterated 2-methyl-pentyl, optionally deuterated methoxy, optionally deuterated ethoxy, optionally deuterated n-propoxy, optionally deuterated isopropoxy, optionally deuterated allyloxy, optionally deuterated prop-2-yn-1-yloxy, optionally deuterated n-butoxy, optionally deuterated iso-butoxy, optionally deuterated tert-butoxy, optionally deuterated pentyl-oxy, optionally deuterated 4-methyl-butoxy, optionally deuterated hexyl-oxy, optionally deuterated 4-methylpentoxy, optionally deuterated cyclopropyloxy, optionally deuterated cyclopropylmethoxy, optionally deuterated cyclopropylethoxy, optionally deuterated cyclobutyloxy, optionally deuterated cyclobutyloxy, optionally deuterated cyclobutylmethoxy, optionally deuterated cyclobutylethoxy, optionally deuterated C_{1-6} haloalkoxy, $-OCF_3$, -

OCF_2CF_3, -$OCHF_2$, -$OCDF_2$, -CF_3, -CF_2CF_3, -CHF_2, CDF_2 -CH_2CF_3, -CD_2CF_3, –CH_2F, -CF_2CH_3 1,1,2,2-tetrafluorobutyl and 1,1,1,2,2-pentafluorobutyl.




9. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-8, wherein R_2, provided R_2 is not forming a ring system with R_{2b}, is selected from the group consisting of methoxy, ethoxy, n-propoxy, isopropoxy, allyloxy, prop-2-yn-1-yloxy, n-butoxy, iso-butoxy, tert-butoxy, pentyl-oxy, 4-methyl-butoxy, hexyl-oxy, 4-methylpentoxy, cyclopropyloxy, cyclopropylmethoxy, cyclopropylethoxy, cyclobutyloxy, cyclobutylmethoxy, cyclobutylethoxy, 2-fluoroethoxy, 3-fluoropropoxy, 4-fluorobutoxy, 2-fluoroethoxy, 3-fluoropropoxy, 2,2-difluoroethoxy, 4-methoxybutoxy, 2-hydroxyethoxy, 1,2-dihydroxyethyl, 2-hydroxy-2,3-dimethylbutoxy, -OCF_3 and (1,3-difluoropropan-2-yl)oxy.

10. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-9, wherein R_2 is selected from the group consisting of methoxy, ethoxy, n-propoxy, isopropoxy, allyloxy, prop-2-yn-1-yloxy, n-butoxy, iso-butoxy, tert-butoxy, pentyl-oxy, 4-methyl-butoxy, hexyl-oxy, 4-methylpentoxy, cyclopropyloxy, cyclopropylmethoxy, cyclopropylethoxy, cyclobutyloxy, cyclobutylmethoxy, cyclobutylethoxy, 2-fluoroethoxy, 3-fluoropropoxy, 4-fluorobutoxy, 2-fluoroethoxy, 3-fluoropropoxy, 2,2-difluoroethoxy, 4-methoxybutoxy, 2-hydroxyethoxy, 1,2-dihydroxyethyl, 2-hydroxy-2,3-dimethylbutoxy, -OCF_3 and (1,3-difluoropropan-2-yl)oxy; and R_{2a}, R_{2b}, R_{2c} and R_{2d} are hydrogen; or R_2 and R_{2b}, taken together with the phenyl ring they attach to and the atoms to which they are attached form a bicyclic fused ring system, that has the following general formula:



(III),

wherein R_{12a} and R_{12b} are hydrogen or methyl, and both R_{13a} and R_{13b} are hydrogen or methyl, and R_{2a}, R_{2c} and R_{2d} are hydrogen.

11. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-10, wherein R_2 is selected from the group consisting of ethoxy, isopropoxy, n-propoxy, allyloxy, n-butoxy, iso-butoxy, tert-butoxy, cyclopropyloxy, cyclopropylmethoxy, 2-fluoroethoxy, 3-fluoropropoxy and 2,2-difluoroethoxy, R_{2a}, R_{2b}, R_{2c} and R_{2d} are hydrogen; or R_2 and R_{2b}, taken together with the phenyl ring they attach to and the atoms to which they are attached form a bicyclic fused ring system, that, has the following formulae  (IIIa),  (IIIb), and  (IIIc), and R_{2a}, R_{2c} and R_{2d} are hydrogen.

12. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-10, wherein R_2 is selected from the group consisting of ethoxy, n-propoxy, isopropoxy, allyloxy, iso-butoxy, tert-butoxy, cyclopropyloxy, cyclopropylmethoxy, 2-fluoroethoxy, 3-fluoropropoxy, 2,2-difluoroethoxy; or R_2 and R_{2b}, taken together with the phenyl ring they attach to and the atoms to which they are attached form unsubstituted 2,3-dihydrobenzofuran-5-yl, unsubstituted benzofuran-5-yl, and unsubstituted 2,2-dimethyl-2,3-dihydrobenzofuran-5-yl.

13. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-12, wherein halogen is fluoro.

14. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-13, wherein R_3 is selected from the group consisting of hydrogen, deuterium, hydroxyl, -OD, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{1-6} alkoxy, substituted or unsubstituted -$(CH_2)_s$-C_{3-6} cycloalkyl, substituted or unsubstituted -$(CH_2)_s$-C_{2-5} heteroalicyclyl,

substituted or unsubstituted -$(CH_2)_s$-C_{2-5} heteroaryl, and substituted or unsubstituted -$(CH_2)_s$-C_{5-6} aryl, wherein each s is selected from the group consisting of 0, 1, 2 and 3.

15. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-14, wherein R_3 is selected from the group consisting of hydrogen, methyl, -CD_3. ethyl, -CD_2CD_3, n-propyl, -$CD_2CD_2CD_3$, iso-propyl, cyclopropyl, -$CDCD_3CD_3$, –$(CR_{9a}R_{9b})_tC(=O)OR_{9c}$ and –$(CH_2)_tC(=O)NR_{9a}R_{9b}$, wherein R_{9a} ,$R_{9b,}$ and R_{9c} independently are hydrogen or C_{1-4}-alkyl, wherein each t is selected from the group consisting of 0, 1, 2 and 3.

16. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-15, wherein R_3 is hydrogen or methyl.

17. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-16, wherein R_{4a}, R_{4b}, R_{5a} and R_{5b} are independently hydrogen or methyl.

18. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-17, wherein R_{4a}, R_{4b} and R_{5a} are hydrogen and R_{5b} is methyl or hydrogen.

19. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-17, wherein R_{4a}, R_{5a} and R_{5b} are hydrogen and R_{4b} is methyl or hydrogen.

20. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-19, wherein R_{4a}, R_{4b}, R_{5a} and R_{5b} are hydrogen.

21. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-20, wherein q is 0, or R_6 is selected from halogen and C_{1-4} alkyl.

22. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-21, wherein q is 1.

23. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to claim 22, wherein R_6 is fluoro.

24. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-23, wherein p is 0.

25. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-24, wherein R_8 is selected from the group consisting of hydrogen, halogen, methyl, ethyl, propyl, methoxy, ethoxy, C_{1-2-} haloalkyl, and C_{1-2-} haloalkoxy.

26. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-25, wherein R_8 is selected from the group consisting of hydrogen, $-CF_3$, $-CHF_2$, $-CF_2CF_3$ $-OCF_3$, $-OCF_2CF_3$ and $–OCHF_2$.

27. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-26, wherein R_8 is hydrogen.

28. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-27, wherein X is O.

29. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-28, wherein m, and n independently are selected from the group consisting of 0 and 1.

30. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-29, wherein m is 1 and n is 0 or 1.

31. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-12, wherein:

R_{4a}, R_{4b}, R_{5a}, R_{5b}, R_6, R_7, R_8 are each hydrogen;

m and n are each 1;

p and q are 0 or 1;

X is O; and

R_3 is selected from the group consisting of hydrogen, methyl, -CD_3. ethyl, -CD_2CD_3, n-propyl, -$CD_2CD_2CD_3$, iso-propyl, cyclopropyl, -$CDCD_3CD_3$, –$(CR_{9a}R_{9b})_tC(=O)OR_{9c}$ and –$(CH_2)_tC(=O)NR_{9a}R_{9b}$, wherein R_{9a} ,$R_{9b,}$ and R_{9c} independently are hydrogen or C_{1-4}-alkyl, wherein each t is selected from the group consisting of 0, 1, 2 and 3.

32. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-12, wherein:

R_{4a}, R_{4b}, R_{5a}, R_{5b}, R_6, R_7, R_8 are each hydrogen;

m and n are each 1;

p and q are 0;

X is O; and

R_3 is selected from the group consisting of hydrogen, methyl, -CD_3. ethyl, -CD_2CD_3, n-propyl, -$CD_2CD_2CD_3$, iso-propyl, cyclopropyl, -$CDCD_3CD_3$, –$(CR_{9a}R_{9b})_tC(=O)OR_{9c}$ and –

$(CH_2)_tC(=O)NR_{9a}R_{9b}$, wherein R_{9a} ,$R_{9b,}$ and R_{9c} independently are hydrogen or C_{1-4}-alkyl, wherein each t is selected from the group consisting of 0, 1, 2 and 3.

33. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to claim 31 or 32, wherein R_3 is methyl or hydrogen.

34. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 31- 33, wherein R_2 is selected from the group consisting of ethoxy, n-propoxy, isopropoxy, allyloxy, iso-butoxy, tert-butoxy, cyclopropyloxy, cyclopropylmethoxy, 2-fluoroethoxy, 3-fluoropropoxy and 2,2-difluoroethoxy; or R_2 and R_{2b}, taken together with the phenyl ring they attach to and the atoms to which they are attached form unsubstituted 2,3-dihydrobenzofuran-5-yl, unsubstituted benzofuran-5-yl, and unsubstituted 2,2-dimethyl-2,3-dihydrobenzofuran-5-yl.

35. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-34, having a hERG % inhibition of less than 65 %, such as less than 50 %, such as less than 40 %, such as less than 30%.

36. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-34, having a hERG % inhibition of less than 65 %, such as less than 50 %, such as less than 40 %, such as less than 30%, and a 5-HT2A pKi of 8.4 or greater

37. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to claim 1, selected from the group consisting of:

1-[(2,4-dimethoxyphenyl)methyl]-3-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-3-[(4-fluorophenyl)methyl]urea;

1-[(2,4-dimethoxyphenyl)methyl]-3-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-3-[(4-fluorophenyl)methyl]urea;
3-[(2,4-dimethoxyphenyl)methyl]-3-(1-methylpiperidin-4-yl)-1-{[4-(2-methylpropoxy)-phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)-phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(2-methylpropoxy)phenyl]methyl}-1-(piperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]-methyl}urea;
3-{[3-fluoro-4-(2-methylpropoxy)phenyl]methyl}-1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-{[2-fluoro-4-(2-methylpropoxy)phenyl]methyl}-1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(4-fluoro-2-hydroxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)-phenyl]methyl}urea;
1-[(4-fluorophenyl)methyl]-3-{[2-hydroxy-4-(2-methylpropoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(2-fluoroethoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-ethoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(4-cyclopropoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-{[4-(tert-butoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-(4-(allyloxy)benzyl)-1-(2,4-difluorobenzyl)-1-(1-methylpiperidin-4-yl)urea;

3-[(1-benzofuran-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-methyl-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2-methyl-1,3-benzoxazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-2,3-dihydro-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-methyl-1,2-benzoxazol-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1,2-dimethyl-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(4-cyclopropoxyphenyl)methyl]-1-[1-(2,4-difluorophenyl)ethyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)-1-[(quinolin-6-yl)methyl]urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-methyl-1,2-benzoxazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(1,3-benzoxazol-6-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(1,3-benzoxazol-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-7-yl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(2,2-dimethyl-2H-chromen-7-yl)methyl]-3-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-1H-indazol-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(2-methyl-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1,1-dioxo-2,3-dihydro-1λ^6-benzothiophen-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,3-dihydro-1H-inden-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(1,3-benzothiazol-6-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2H-indazol-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-methyl-2H-indazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(4-cyano-2-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2-fluoro-4-nitrophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-{[2-($^2H_3$)methyl(1,1,1,3,3,3-$^2H_6$)propan-2-yl]oxy}phenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(4-cyclopropoxyphenyl)methyl]-1-[(1R)-1-(2,4-difluorophenyl)ethyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(3-cyano-4-methoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2-chloro-4-methoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-methoxy-2-(trifluoromethyl)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;

3-[(2,4-difluorophenyl)methyl]-1-[(2-fluoro-4-nitrophenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
N-(5-fluoro-2-{[1-(1-methylpiperidin-4-yl)({[4-(propan-2-yloxy)phenyl]methyl}carbamoyl)amino]methyl}phenyl)acetamide
1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-1H-1,3-benzodiazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-1H-indazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-dichlorophenyl)methyl]-3-{[4-(2-methylpropoxy)phenyl]methyl}-1-(piperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-4-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(4-chloro-2-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-methoxyphenyl)methyl]-1-(piperidin-4-yl)urea;
1-[(2-chloro-4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}-1-[(2,3,6-trifluorophenyl)methyl]urea;
3-[(4-chloro-2-methoxyphenyl)methyl]-3-(1-methylpiperidin-4-yl)-1-{[4-(2-methylpropoxy)phenyl]methyl}urea;
3-{[4-methoxy-2-(trifluoromethyl)phenyl]methyl}-3-(1-methylpiperidin-4-yl)-1-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-{[2-chloro-4-(trifluoromethyl)phenyl]methyl}-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-{[2-fluoro-4-(trifluoromethyl)phenyl]methyl}-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-{[4-chloro-2-(trifluoromethyl)phenyl]methyl}-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;

1-[(2-chloro-4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;

1-[(4-chloro-2,6-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;

1-[(2,4-dichlorophenyl)methyl]-1-(piperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,6-difluoro-3-methylphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-3-{[4-($^{2}H_3$)methoxyphenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-{[2-methoxy-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-1-{1-[(1,1,1,3,3,3-$^{2}H_6$)propan-2-yl]piperidin-4-yl}-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-[(4-propoxyphenyl)methyl]urea;

3-[(1H-1,3-benzodiazol-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(7R,8aS)-octahydroindolizin-7-yl]-3-[(4-cyclopropoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]urea;

1-[(7R,8aS)-octahydroindolizin-7-yl]-1-[(2,4-difluorophenyl)methyl]-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-[(quinoxalin-6-yl)methyl]urea;

1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[(quinoxalin-6-yl)methyl]urea

3-[(4,5-difluoro-2-methoxyphenyl)methyl]-3-(piperidin-4-yl)-1-{[4-(propan-2-yloxy)phenyl]methyl}urea;

3-[(2,4-difluorophenyl)methyl]-3-[(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-1-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-1-[(3R,4S)-1,3-dimethylpiperidin-4-yl]-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-1-[(3S,4R)-1,3-dimethylpiperidin-4-yl]-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-1-(1,4-dimethylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(2-hydroxy-2,3-dimethylbutoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-({3-fluoro-4-[(2-hydroxyethoxy)methyl]phenyl}methyl)-1-(1-methylpiperidin-4-yl)urea;
N-(5-fluoro-2-{[1-(1-methylpiperidin-4-yl)({[4-(propan-2-yloxy)phenyl]methyl}carbamoyl)-amino]methyl}phenyl)acetamide;
1-{[2-hydroxy-4-(trifluoromethyl)phenyl]methyl}-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-[(4-fluoro-2-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
5-fluoro-2-{[1-(1-methylpiperidin-4-yl)({[4-(2-methylpropoxy)phenyl]methyl}-carbamoyl)amino]methyl}phenyl acetate;
1-[(2,4-difluorophenyl)methyl]-3-[(1H-indazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-({4-[(1R)-1,2-dihydroxyethyl]phenyl}methyl)-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-({4-[(1S)-1,2-dihydroxyethyl]phenyl}methyl)-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1,3-dihydro-2-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(3-methoxypropoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2-fluoro-4-nitrophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(4-chloro-3-methoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-fluoro-2-(trifluoromethoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;

3-[(2,4-difluorophenyl)methyl]-1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-{[2-(difluoromethoxy)-4-fluorophenyl]methyl}-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-{[4-chloro-2-(trifluoromethyl)phenyl]methyl}-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-{[4-fluoro-2-(trifluoromethoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-[(4-fluoro-2-methylphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-[(2-chloro-4-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-[(2,4-dichlorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-dichlorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-[(2,4-dichlorophenyl)methyl]-1-(piperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2-chloro-4-fluorophenyl)methyl]-3-{[4-(2-methylpropoxy)phenyl]methyl}-1-(piperidin-4-yl)urea;
1-[(2-chloro-4-fluorophenyl)methyl]-1-(piperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-dichlorophenyl)methyl]-3-{[4-(2-methylpropoxy)phenyl]methyl}-1-(piperidin-4-yl)urea;
1-[(2,4-difluoro-3-methylphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)-phenyl]methyl}urea;
1-[(2-fluoro-4-methylphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-{[2-methyl-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(4-cyclopropoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]urea;
1-[(4-cyclopropoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]urea;

1-[(2,4-difluorophenyl)methyl]-3-[(3-fluoro-4-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2-fluoro-4-hydroxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)-1-[(4-phenoxyphenyl)methyl]urea;
3-{[4-methoxy-2-(trifluoromethyl)phenyl]methyl}-3-(1-methylpiperidin-4-yl)-1-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-[(2-fluoro-4-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
3-[(4-butoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)urea;
3-[(4-butoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-methoxyphenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-methoxyphenyl)methyl]-1-(piperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-ethoxyphenyl)methyl]-3-(piperidin-4-yl)urea;
3-[(2H-1,3-benzodioxol-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(3,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]-methyl}urea;
1-[(2,4-difluorophenyl)methyl]-1-[1-($^{2}H_3$)methylpiperidin-4-yl]-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-(piperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}-1-[(2,3,4-trifluorophenyl)methyl]urea;
3-[(4-chloro-2-fluorophenyl)methyl]-3-(piperidin-4-yl)-1-{[4-(propan-2-yloxy)phenyl]-methyl}urea;
3-[(4-chloro-2-fluorophenyl)methyl]-1-{[4-(2-methylpropoxy)phenyl]methyl}-3-(piperidin-4-yl)urea;
1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}-1-[(2,3,4-trifluorophenyl)methyl]urea;
1-[(2,6-difluoro-4-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(4-chloro-2-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(4,5-difluoro-2-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(4-chloro-2-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[(4-propoxyphenyl)methyl]urea;
3-{[4-(cyclopropylmethoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[3-fluoro-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[2-fluoro-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[3-methyl-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-fluoro-3-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-({4-[(2-ethylhexyl)oxy]phenyl}methyl)-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(prop-2-yn-1-yloxy)phenyl]methyl}urea;
3-{[4-(tert-butoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)urea;
1-[(2,6-difluoro-4-methoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-{[4-(3-fluoropropoxy)phenyl]methyl}-3-(1-methylpiperidin-4-yl)urea;
1-{[4-(1,1-difluoroethyl)phenyl]methyl}-3-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-({4-[(1,3-difluoropropan-2-yl)oxy]phenyl}methyl)-3-(1-methylpiperidin-4-yl)urea;
3-{[4-(2,2-difluoroethoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-methoxyphenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
1-[(4-cyclopropoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-(piperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(piperidin-4-yl)urea; and
1-[(2,4-difluorophenyl)methyl]-3-{[2,3-dihydro(2,2,3,3-$^{2}H_{4}$)-1-benzofuran-5-yl]methyl}-1-(1-methylpiperidin-4-yl)urea.

38. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to claim 1, selected from the group consisting of:
1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-[(4-propoxyphenyl)methyl]urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[(4-propoxyphenyl)methyl]urea;
3-{[4-(cyclopropylmethoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methyl-piperidin-4-yl)urea;
1-[(4-cyclopropoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-(piperidin-4-yl)urea;
3-{[4-(2,2-difluoroethoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-{[4-(tert-butoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)urea;
3-(4-(allyloxy)benzyl)-1-(2,4-difluorobenzyl)-1-(1-methylpiperidin-4-yl)urea;
3-[(4-cyclopropoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(2-fluoroethoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
3-[(1-benzofuran-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-{[4-(3-fluoropropoxy)phenyl]methyl}-3-(1-methylpiperidin-4-yl)urea;

3-{[4-(tert-butoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-ethoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea; and
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea.

39. Use of an effective amount of a compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-38, or a composition comprising an effective amount of a compound, pharmaceutically acceptable salt, polymorph or stereoisomer of a compound according to any one of claims 1-38 for the production of a medicament for treating a disease in a patient, wherein the disease is selected from the group consisting of Abnormal hormonal activity, Alzheimer's disease, Alzheimer’s disease dementia, Alzheimer’s disease psychosis, Addiction (alcohol, cocaine, methamphetamine, nicotine and opioid), Addison’s disease, ADHD, Alzheimer's disease psychosis, Affective disorders, Aggressiveness, Agitation, Akathisia, Alcohol addiction, Alcohol withdrawal, Amenorrhea, Amyotrophic lateral sclerosis, Anhedonia, Anorexia, Anti-NMDAR encephalitis, Anxiety, Appetite disorders, Asthma, Autism, Behavioral disorders, Behavioral disturbances associated with dementia, Binge eating disorder associated with impulse control disorder (ICD), Bipolar disorder, Blindness, Borderline disorder, Borderline personality disorder, Bradykinesia, Bulimia, Buying associated with ICD, Cardiac arrhythmia, Cerebral vascular accidents, Charles Bonnet disease, Chemotherapy-induced emesis, Childhood autism, Chronic pain, Chronic insomnia, cocaine addiction, Cognitive disorders, craniofacial pain, temporomandibular joint (TMJ) / temporomandibular disorder (TMD), Cushing´s disease, Delusion, Dementia, Dementia with Lewy Body or Lewy Body dementia, dementia and psychosis associated with Creutzfeld-Jakob disease (CJD), Gerstmann-Strausser-Schenker disease (GSSD) and fatal familiar insomnia (FFI), Depression, Diabetes mellitus (non-insulin

dependent), Diabetic peripheral neuropathy, Drug addiction, Double vision, Down´s syndrome, Dyskinesia, Dysthymia, Dystonia, Ejaculatory problem, Emphysema, Epilepsy, Extrapyramidal disorder, Fibromyalgia, Frailty, Friedrich´s Ataxia, Frontotemperal Dementia, Gambling associated with ICD, Galactorrhea, General anxiety disorder, Glaucoma, Hair loss or thinning, Hallucination, Headache, Hemorrhoids, Huntington's disease, Hyperprolactinemia, Hypertension, Hypersexuality associated with ICD, Hypotension, Hypoglutamateriga disorders, Impulse control disorder, Idiopathic thrombocytopenic purpura, Impotence, Incontinence, Increased intraocular pressure, Infertility, Inflammatory pain, Insomnia, Ischemia, Ischemic stroke, Lewy body disease (LBD), Learning disorders, Libido (decreased), Loss of libido, Low male fertility, Low sperm mobility, Lupus, Machado-Joseph disease, Major depression, Mania, Menopausal symptoms, Metabolic syndrome, methamphetamine addiction, Migraine, mild cognitive impairment (MCI), Motor tics, Multi-infarct dementia, Multiple sclerosis, Multiplex development disorder, Myocardial infarction, Myoclonus, Neuropathic pain, Neurodegenerative disorder, Neuropsychiatric disease, Nicotine addiction, Non motor symptoms of Parkinson's disease selected from dementia, depression, apathy, hallucinations, dribbling saliva (sialorrhea), constipation, pain, genitourinary problems and sleep disorders, Obsessive compulsive disorder, On/off phenomena, Opioid addiction, Osteoporosis, Pancreatis, Panic attacks, Parkinson's disease, Parkinson's disease dementia, Parkinson's disease psychosis, Periodic limb movement during sleep (PLMS), Peripheral vascular disease, Pituitary tumor, Postherpetic neuralgia, Progressive Supranucelar Palsy, Prion disease including Creutzfeld-Jakob disease (CJD), Gerstmann-Strausser-Schenker disease (GSSD) and fatal familiar insomnia (FFI), Prolactinoma, Pseudobulbar affect (PBA), Psychomotor slowing, Psychosis, Psychoses secondary to neurodegenerative disorders, Psychosomatic disorders, Psychotic depression, post-traumatic stress disorder (PTSD), Raynaud´s disease, Reflex sympathetic dystrophy, Restless legs syndrome, Retinal disease, Schizoaffective disorders, Schizophrenia, negative symptoms of schizophrenia, cognitive impairment associated with schizophrenia, Sepsis, Serotonin syndrome, Sexual dysfunction, Sexual dysfunction associated with antidepressant use, Sleep apnea, Sleep disorders, Sleep maintenance insomnia, social anxiety disorder, Spinal injury, Spinocerebellar Atrophy, Suicidal tendency, Thrombosis, Thrombotic stroke, Thrombotic thrombocytopenic purpura, Tinnitus, Tiredness, Tourette´s syndrome, Transient insomnia, Traumatic brain injury, Treatment-resistant depression, Treatment-resistant schizophrenia, Tremor, Vaginal dryness,

Vasospasm Wakefulness, vascular dementia, Hallucinations associated with Parkinson’s disease, Delusions associated with Parkinson’s disease; cancer, brain cancer, glioma, Pancreatic cancer, Hypoactive sexual desire disorder, adult type 2 diabetes mellitus with Parkinson’s disease or dementia and Liver fibrosis.

40. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, prodrug, stereoisomer, and deuterated analogue thereof according to any one of claims 1-38, or a composition comprising an effective amount of a compound, pharmaceutically acceptable salt, polymorph or stereoisomer of a compound according to any one of claims 1-38,
for use in treating a disease selected from the group consisting of Abnormal hormonal activity, Alzheimer's disease, Alzheimer’s disease dementia, Alzheimer’s disease psychosis, Addiction (alcohol, cocaine, methamphetamine, nicotine and opioid), Addison’s disease, ADHD, Alzheimer's disease psychosis, Affective disorders, Aggressiveness, Agitation, Akathisia, Alcohol addiction, Alcohol withdrawal, Amenorrhea, Amyotrophic lateral sclerosis, Anhedonia, Anorexia, Anti-NMDAR encephalitis, Anxiety, Appetite disorders, Asthma, Autism, Behavioral disorders, Behavioral disturbances associated with dementia, Binge eating disorder associated with impulse control disorder (ICD), Bipolar disorder, Blindness, Borderline disorder, Borderline personality disorder, Bradykinesia, Bulimia, Buying associated with ICD, Cardiac arrhythmia, Cerebral vascular accidents, Charles Bonnet disease, Chemotherapy-induced emesis, Childhood autism, Chronic pain, Chronic insomnia, cocaine addiction, Cognitive disorders, craniofacial pain, temporomandibular joint (TMJ) / temporomandibular disorder (TMD), Cushing´s disease, Delusion, Dementia, Dementia with Lewy Body or Lewy Body dementia, dementia and psychosis associated with Creutzfeld-Jakob disease (CJD), Gerstmann-Strausser-Schenker disease (GSSD) and fatal familiar insomnia (FFI), Depression, Diabetes mellitus (non-insulin dependent), Diabetic peripheral neuropathy, Drug addiction, Double vision, Down´s syndrome, Dyskinesia, Dysthymia, Dystonia, Ejaculatory problem, Emphysema, Epilepsy, Extrapyramidal disorder, Fibromyalgia, Frailty, Friedrich´s Ataxia, Frontotemperal Dementia, Gambling associated with ICD, Galactorrhea, General anxiety disorder, Glaucoma, Hair loss or thinning, Hallucination, Headache, Hemorrhoids, Huntington’s disease, Hyperprolactinemia, Hypertension, Hypersexuality associated with ICD, Hypotension, Hypoglutamateriga disorders, Impulse control disorder, Idiopathic thrombocytopenic purpura, Impotence, Incontinence,

Increased intraocular pressure, Infertility, Inflammatory pain, Insomnia, Ischemia, Ischemic stroke, Lewy body disease (LBD), Learning disorders, Libido (decreased), Loss of libido, Low male fertility, Low sperm mobility, Lupus, Machado-Joseph disease, Major depression, Mania, Menopausal symptoms, Metabolic syndrome, methamphetamine addiction, Migraine, mild cognitive impairment (MCI), Motor tics, Multi-infarct dementia, Multiple sclerosis, Multiplex development disorder, Myocardial infarction, Myoclonus, Neuropathic pain, Neurodegenerative disorder, Neuropsychiatric disease, Nicotine addiction, Non motor symptoms of Parkinson's disease selected from dementia, depression, apathy, hallucinations, dribbling saliva (sialorrhea), constipation, pain, genitourinary problems and sleep disorders, Obsessive compulsive disorder, On/off phenomena, Opioid addiction, Osteoporosis, Pancreatis, Panic attacks, Parkinson's disease, Parkinson's disease dementia, Parkinson's disease psychosis, Periodic limb movement during sleep (PLMS), Peripheral vascular disease, Pituitary tumor, Postherpetic neuralgia, Progressive Supranucelar Palsy, Prion disease including Creutzfeld-Jakob disease (CJD), Gerstmann-Strausser-Schenker disease (GSSD) and fatal familiar insomnia (FFI), Prolactinoma, Pseudobulbar affect (PBA), Psychomotor slowing, Psychosis, Psychoses secondary to neurodegenerative disorders, Psychosomatic disorders, Psychotic depression, post-traumatic stress disorder (PTSD), Raynaud´s disease, Reflex sympathetic dystrophy, Restless legs syndrome, Retinal disease, Schizoaffective disorders, Schizophrenia, negative symptoms of schizophrenia, cognitive impairment associated with schizophrenia, Sepsis, Serotonin syndrome, Sexual dysfunction, Sexual dysfunction associated with antidepressant use, Sleep apnea, Sleep disorders, Sleep maintenance insomnia, social anxiety disorder, Spinal injury, Spinocerebellar Atrophy, Suicidal tendency, Thrombosis, Thrombotic stroke, Thrombotic thrombocytopenic purpura, Tinnitus, Tiredness, Tourette´s syndrome, Transient insomnia, Traumatic brain injury, Treatment-resistant depression, Treatment-resistant schizophrenia, Tremor, Vaginal dryness, Vasospasm Wakefulness, vascular dementia, Hallucinations associated with Parkinson's disease, Delusions associated with Parkinson's disease; cancer, brain cancer, glioma, Pancreatic cancer, Hypoactive sexual desire disorder, adult type 2 diabetes mellitus with Parkinson's disease or dementia and Liver fibrosis.